Resistance to apoptosis is a critical feature of neoplastic cells. Galectin-1 is an endogenous carbohydrate-binding protein that induces death of leukemia and lymphoma cells, breast cancer cells, and the LNCaP prostate cancer cell line, but not other prostate cancer cell lines. To understand the mechanism of galectin-1 sensitivity of LNCaP cells compared with other prostate cancer cells, we characterized glycan ligands that are important for conferring galectin-1 sensitivity in these cells, and analyzed expression of glycosyltransferase genes in galectin-1-sensitive, prostate-specific antigen-positive (PSA + ) LNCaP cells compared with a galectin-1-resistant PSA À LNCaP subclone. We identified one glycosyltransferase, core 2 N-acetylglucosaminyltransferase, which is downregulated in galectin-1-resistant PSA À LNCaP cells compared with galectin-1-sensitive PSA + LNCaP cells. Intriguingly, this is the same glycosyltransferase required for galectin-1 susceptibility of T lymphoma cells, indicating that similar O-glycan ligands on different polypeptide backbones may be common death trigger receptors recognized by galectin-1 on different types of cancer cells. Blocking O-glycan elongation by expressing A2,3-sialyltransferase 1 rendered LNCaP cells resistant to galectin-1, showing that specific O-glycans are critical for galectin-1 susceptibility. Loss of galectin-1 susceptibility and synthesis of endogenous galectin-1 has been proposed to promote tumor evasion of immune attack; we found that galectin-1-expressing prostate cancer cells killed bound T cells, whereas LNCaP cells that do not express galectin-1 did not kill T cells. Resistance to galectin-1-induced apoptosis may directly contribute to the survival of prostate cancer cells as well as promote immune evasion by the tumor. [Cancer Res 2007;67(13):6155-62] 
Introduction
Specific alterations in the glycosylation pattern of cell-surface glycoproteins and glycolipids occur during cellular transformation and tumor progression (1) (2) (3) (4) (5) (6) . These novel ''glyco-epitopes'' are proposed to facilitate tumor progression by several mechanisms, which include promoting cellular detachment from basement membrane and migration to sites of metastasis, masking of tumor cells to avoid an immune response, and protecting tumor cells from endogenous inducers of apoptosis (1, 5, 7, 8) .
Altered tumor cell glycosylation as well as changes in expression of glycan-binding lectins by tumor cells and stroma has been described in prostate cancer, the most common cancer in men and the second highest cause of cancer deaths in Western society (3, 4, (9) (10) (11) (12) (13) (14) (15) (16) (17) . Changes in prostate cancer cell glycosylation have been proposed to affect prostate cancer cell growth, invasion and metastasis, and progression to androgen independence. For example, prostate-specific antigen (PSA) from cancer patients typically bears increased levels of a2,3-linked sialic acid compared with PSA from patients with benign prostatic hyperplasia (18) . Similarly, the tumor cell-surface glycoprotein prostate mucin antigen, which bears abundant O-glycans, is expressed on prostate tumor cells but not on normal prostate cells (19) . O-Glycans on prostate cancer cells often bear the Tn antigen (GalNAc-O-Ser/Thr), a glyco-epitope that has been proposed as a target for tumor immunotherapy (20) , and the T antigen on O-glycans (Galh1,3GalNAc) plays a role in prostate cancer cell adhesion to endothelium (21) .
Several members of the galectin family of lectins are aberrantly expressed in prostate cancer and have been implicated in the process of prostate cancer progression (9) (10) (11) (12) (13) (14) (15) (16) (17) (21) (22) (23) (24) (25) (26) . Galectins are soluble carbohydrate-binding proteins that can remain intracellular, where they regulate cell signaling and cell survival, or can be secreted via a nonclassic pathway to mediate cell-cell and cellmatrix interactions (27) . Galectin-8, also known as prostate carcinoma tumor antigen 1, is selectively expressed in prostate carcinoma, compared with normal or benign hyperplastic prostate (16, 17) . As galectin-8 modulates cell adhesion to extracellular matrix proteins such as fibronectin, galectin-8 may be involved in tumor cell invasion. Galectin-3 is proposed to have both intracellular and extracellular functions in prostate cancer. Cytoplasmic galectin-3 promotes prostate cancer cell resistance to apoptosis, anchorage-independent growth, and invasion into extracellular matrix, whereas extracellular galectin-3 mediates prostate cell attachment to endothelial cells (9) (10) (11) (12) (21) (22) (23) (24) (25) .
Galectin-1 acts extracellularly to induce apoptosis of normal and transformed T lymphocytes, as well as breast and trophoblast tumor cells (27, 28) . Whereas specific types of cell-surface glycosylation are known to create or mask the glycan ligands required for galectin-1-induced T-lymphocyte cell death (8, (29) (30) (31) , nothing is known about features of cell-surface glycosylation that regulate epithelial cancer cell susceptibility to galectin-1. Expression of galectin-1 by LNCaP prostate cancer cells, either by treatment with sodium butyrate or transfection with rat galectin-1 cDNA, induced apoptosis of this cell line, although these studies did not examine secretion of galectin-1 by the LNCaP cells, nor were glycan ligands for galectin-1 characterized (26) . In contrast, the prostate cancer cell lines DU145 and PC-3 synthesize and secrete abundant galectin-1, implying that these cell lines are resistant to death triggered by galectin-1 (25) . Similarly, a PSA LNCaP subclone showed a >25-fold increase in expression of galectin-1 mRNA and increased expression of galectin-1 protein, compared with androgen-dependent PSA + LNCaP cells (32, 33) . Because loss of PSA expression is correlated with progression to a more aggressive tumor, the robust expression of galectin-1 by PSA À LNCaP cells suggested a correlation between increasing galectin-1 expression and prostate cancer cell progression. Similarly, Castronovo and colleagues have found that increasing expression of galectin-1 in prostate tumor stroma correlates with tumor aggressiveness and poor prognosis in prostate cancer patients, implying that tumor cell acquisition of resistance to galectin-1-induced cell death confers a selective advantage to tumor cells that can evade galectin-1-induced cell death (14) . Moreover, recent work in a murine melanoma model showed that melanoma expression of galectin-1 induced death of infiltrating T cells, whereas suppression of tumor cell expression of galectin-1 enhanced CD8 T-cell attack of the tumor (34) . We have directly shown that galectin-1 in extracellular matrix can kill infiltrating T cells (35) . Thus, resistance to galectin-1 apoptosis may enhance prostate cancer cell metastasis as well as evasion of an immune response.
As mentioned above, the specific glycan ligands bound by galectin-1 to trigger cell death have not been identified in prostate cancer cells. In the present study, we identify a specific glycan structure required for galectin-1 to induce death of LNCaP cells. Importantly, this glycan ligand on LNCaP cells that is required for susceptibility to galectin-1-induced cell death is the same structure required for T-cell susceptibility to galectin-1 (29, 30) ; as prostate cancer cells do not express the T-cell glycoprotein receptors that participate in galectin-1-induced cell death (CD45, CD43, and CD7; refs. 30, 36, 37) , these data indicate that galectin-1-induced death of epithelial and mesenchymal cells involves a common saccharide ligand that can be attached to different polypeptide backbones on different cell types. Finally, we find that prostate cancer cells expressing galectin-1 are potent inducers of T-cell apoptosis, supporting the model that galectin-1 expression by tumor cells promotes evasion of an immune response (34, 35, 38) .
Materials and Methods
Cell lines. The human prostate cell lines LNCaP, PC-3, and DU145 and the human T-cell line CEM were obtained from the American Type Culture Collection. CEM, LNCaP, and the PSA + and PSA À LNCaP subclones (32) were grown in 100 Â 20 mm tissue culture dishes in 10-mL RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 mg/mL streptomycin, and 100 units/mL penicillin. DU145 was grown in DMEM with 10% FBS and PC-3 was grown in Ham's F12K medium with 7% FBS (Life Technologies, Inc.). Cells were maintained in a humidified incubator at 37jC with 5% CO 2 .
Galectin-1 detection. For immunofluorescence microscopy, LNCaP, DU145, and PC-3 were grown for 48 h on glass coverslips until 50% confluent. Cells were fixed with 2% paraformaldehyde in PBS for 30 min on ice, washed with PBS, stained with polyclonal rabbit anti-human galectin-1 antibody (1:500), and bound antibody was detected with fluoresceinconjugated goat anti-rabbit immunoglobulin G (IgG; 1:300; Jackson Immunochemical) exactly as previously described (30) . Slides were analyzed using an Axioskop 2 plus microscope and Axiovision 3.1 software (Zeiss).
For immunoblotting, subconfluent monolayers of prostate cells were removed from plates with PBS-EDTA (5 mmol/L). Cells were lysed in lysis buffer (50 mmol/L Tris-Cl, 1% NP40, 5 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 10 Ag/mL aprotinin, 10 Ag/mL leupeptin, 150 mmol/L NaCl) for 30 min on ice, samples centrifuged to pellet nuclei, and protein concentrations of the supernatants determined by Bio-Rad Protein Assay (Bio-Rad). Equal amounts of total cell protein (20 Ag/lane) were separated by SDS-PAGE and transferred to nitrocellulose membranes; membranes were blocked with 10% nonfat milk and incubated overnight at 4jC with rabbit polyclonal antibody to galectin-1 (1:1,000). Membranes were washed in TBS with 0.5% Tween and incubated with horseradish peroxidase-conjugated goat anti-rabbit reagent (1:1,000; Bio-Rad). Samples were visualized with Hyperfilm enhanced chemiluminescence (Amersham). To detect equal loading, blots were stripped and reprobed with anti-actin (1:5,000; Sigma-Aldrich).
ELISA quantification of cell-surface galectin-1 was done exactly as in ref. 35 , with 0.02 Â 10 6 to 2 Â 10 6 of the indicated cells added per well, using anti-galectin-1 IgG purified from rabbit polyclonal antiserum to galectin-1. Galectin-1 concentration was determined based on a standard curve using purified recombinant galectin-1.
Galectin-1 prostate cell death assays. Subconfluent monolayers of prostate cell lines grown in 35-mm six-well plates were treated with 20 Amol/L galectin-1 in a final volume of 2-mL PBS with 1. Prostate cell induction of T-cell death. CEM T cells (10 6 ; >98% viable by trypan blue exclusion) in RPMI were added to confluent monolayers of the indicated prostate cell lines for 8 h at 37jC. Plates were vigorously
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Cancer Res 2007; 67: (13) . July 1, 2007 washed by pipetting with PBS or with 0.1 mol/L lactose in PBS to recover T cells. The recovered cells were washed with PBS and assayed by flow cytometric detection of TUNEL labeling (described above) to detect T-cell death. Forward versus side scatter analysis of the cells was used to discriminate T cells from any nonadherent prostate cells that were removed during the wash step; nonadherent prostate cells were <5% of total cells analyzed in all experiments. As a positive control for T-cell death, 10 6 CEM cells were treated with 20 Amol/L recombinant human galectin-1 or buffer alone. Data were acquired using a FACScan flow cytometer and analyzed with CellQuest software.
Results
Galectin-1 expression by prostate cancer cell lines. Galectin-1 is expressed by DU145 and PC-3 prostate cancer cell lines but not by PSA + LNCaP cells (25, 26) . We confirmed that DU145 and PC-3 make abundant galectin-1 whereas LNCaP cells do not produce galectin-1 detected by immunoblotting, as previously shown (refs. 25, 26; Fig. 1A ). Moreover, DU145 and PC-3 cells externalize galectin-1; cell-surface galectin-1 was detected by ELISA ( Fig. 1A) and by immunofluorescent labeling of DU145 and PC-3 cells (Fig. 1B) . Importantly, galectin-1 on DU145 and PC-3 cells can be released by preincubation with lactose (data not shown), showing that secreted endogenous galectin-1 is retained on the cell surface via lectin-carbohydrate interactions.
Prostate cancer cell susceptibility to galectin-1-induced cell death. Because DU145 cells but not LNCaP cells produce and externalize abundant galectin-1, we reasoned that DU145 cells would be resistant to cell death triggered by exogenous galectin-1, whereas LNCaP cells would die after binding exogenous galectin-1. As shown in Fig. 1C and D, LNCaP cells are susceptible to cell death induced by exogenous galectin-1. Importantly, the effect of galectin-1 on LNCaP cells was inhibited by addition of lactose, showing that galectin-1-induced cell death required galectin-1 binding to saccharide ligands on the surface of the LNCaP cells. Cell death was detected by the TUNEL assay, showing that the cells reached a late stage of apoptosis in which DNA degradation has occurred. In contrast to LNCaP cells, DU145 cells were resistant to galectin-1-induced apoptosis (Fig. 1D) , consistent with the observation that DU145 cells synthesize and secrete abundant endogenous galectin-1.
O-Glycans on cellular glycoproteins are required for LNCaP susceptibility to galectin-1-induced death. As shown in Fig. 1 , galectin-1-induced death of LNCaP cells requires galectin-1 binding to saccharide ligands on the cells. Galectin-1 preferentially binds to galactose-terminated saccharide ligands, particularly to lactosamine (Galh1,4GlcNAc) sequences that can be found on N-or O-linked glycans on cell-surface glycoproteins (27, (29) (30) (31) . These lactosamine sequences can be elongated to form polylactosamine structures that are high-avidity ligands for galectin-1. On N-glycans, elongation of polylactosamine sequences is typically initiated by the action of the N-acetylglucosaminyltransferase V enzyme, whereas on O-glycans, elongation of polylactosamine sequences is typically initiated by the action of the core 2 GnT enzyme (29) . Because the lactose inhibition data in Fig. 1D showed that galectin-1-induced death of LNCaP cells required galectin-1 binding to saccharide ligands on the cell surface, we asked if galectin-1-induced death of LNCaP cells required N-or O-glycan structures.
We used inhibitors to modify glycosylation of N-and O-glycans. The inhibitor DMNJ modifies N-glycans by inhibiting mannosidase II, the enzyme that trims high-mannose structures on N-glycans to allow subsequent addition of N-acetylglucosamine residues and elongation of lactosamine sequences (31) . Loss of N-acetylglucosamine sequences, particularly on the glycan branch modified by N-acetylglucosaminyltransferase V, can be detected by loss of staining with the plant lectin PHA. As shown in Fig. 2A , treatment of LNCaP cells with DMNJ markedly reduced PHA staining, indicating the effectiveness of DMNJ treatment in reducing lactosamine addition to N-glycans. To modify O-glycan elongation, we used benzyl-a-GalNAc that can modify O-glycan elongation in two different ways (39) (40) (41) . In cells with low amounts of sialylated O-glycans, benzyl-a-GalNAc blocks elongation of O-glycans beyond the initial GalNAc residue (Fig. 3) , an effect that can be detected by reduced reactivity with the plant lectin PNA. In cells with high levels of sialylated O-glycans, benzyl-a-GalNAc inhibits O-glycan sialylation, resulting in exposure of nonsialylated O-glycans and increased PNA reactivity. As shown in Fig. 2B , treatment of LNCaP cells with benzyl-a-GalNAc resulted in increased PNA binding, indicating that the inhibitor treatment increased exposure of nonsialylated O-glycans on these cells.
LNCaP cells treated with either DMNJ or benzyl-a-GalNAc were assessed for sensitivity to galectin-1-induced cell death. Treatment with DMNJ had no significant effect on LNCaP cell susceptibility to galectin-1 (Fig. 2C) ; as DNMJ treatment did not reduce LNCaP susceptibility to galectin-1, complex N-glycans bearing lactosamine sequences are not required for galectin-1-induced death of these cells. In contrast, treatment of LNCaP cells with benzyl-a-GalNAc, causing increased exposure of nonsialylated O-glycans, resulted in a dramatic increase in sensitivity to galectin-1-induced cell death, with virtually 100% of the cells dying in response to galectin-1 (Fig. 2D) . These results indicated that O-glycans on cell-surface glycoproteins regulate LNCaP cell sensitivity to galectin-1-induced cell death.
Galectin (Fig. 4A) . We confirmed reduced expression of core 2 GnT mRNA in PSA À LNCaP cells compared with PSA + LNCaP cells by RT-PCR analysis (Fig. 4B) .
Core 2 GnT activity creates branched O-glycans bearing lactosamine sequences recognized by galectin-1 (Fig. 3) . Our data indicated that O-glycans participate in galectin-1-induced death of LNCaP cells (Fig. 2C) , suggesting that the reduction in core 2 GnT expression in PSA À LNCaP cells could render the cells resistant to galectin-1-induced cell death. Intriguingly, our group has previously shown that core 2 GnT expression also renders T cells susceptible to galectin-1-induced cell death (29, 30) , indicating that galectin-1 susceptibility of various cell types may be controlled at the level of cell-surface glycosylation by common glycosyltransferase enzymes that add the same glycan ligands to different polypeptides on different cell types.
Blocking O-glycan elongation protects LNCaP cells from galectin-1-induced death. To directly address the role of Oglycans in regulating LNCaP susceptibility to galectin-1, we attempted to decrease core 2 GnT expression in LNCaP cells using small interfering RNA. However, despite repeated attempts, we were unable to reduce core 2 GnT enzyme expression below 40% 
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Cancer Res 2007; 67: (13 39, 42; Fig. 3) . We have previously found that overexpression of ST3Gal1 is an effective method of blocking O-glycan elongation in T cells (39) . As shown in Fig. 5A , expression of ST3Gal1 in LNCaP cells reduced PNA binding to the cells, showing the effectiveness of ST3Gal1 expression in blocking O-glycan elongation. Furthermore, ST3Gal1 expression resulted in a marked reduction in LNCaP cell susceptibility to galectin-1-induced cell death (Fig. 5B and C) . Cells expressing the ST3Gal1 showed >60% reduction in TUNELpositive cells following galectin-1 binding, compared with cells transfected with vector alone. These results show that changes in O-glycan expression and degree of O-glycan sialylation regulate LNCaP cell susceptibility to galectin-1-induced cell death.
Galectin-1-resistant prostate cancer cells express galectin-1 and kill adherent T cells. Galectin-1 expression increases with epithelial cancer progression in prostate, ovarian, and squamous cell carcinomas (13, 14, 43, 44) . Moreover, increased galectin-1 expression in human squamous cell carcinomas and in a mouse melanoma model resulted in decreased T-cell infiltration into the tumors (34, 44) Fig. 6B) . In contrast, we observed a distinct population of TUNEL-positive T cells after binding to PSA À LNCaP cells that express galectin-1. Similarly, we observed robust TUNEL staining of f50% of T cells adherent to PC-3 cells (Fig. 6C) . T cells were directly treated with purified recombinant galectin-1 as a positive control (Fig. 6C) . Thus, prostate cancer cells that have acquired resistance to galectin-1-induced death can express endogenous galectin-1 that can kill T cells, supporting the model that tumor expression of galectin-1 promotes tumor immune privilege.
Discussion
Galectin-1 can kill lymphoid and epithelial tumor cells and has the potential to synergize with other cell death-inducing agents to enhance killing of a variety of tumor cell types (27, 28, 45) . Whereas glycan ligands on T cells recognized by galectin-1 have been identified, little is known about galectin-1 recognition of specific glycans on epithelial neoplasms such as breast and prostate cancer. In this report, we have shown that O-glycans on LNCaP prostate cancer cells are essential for triggering galectin-1-induced cell death, and that masking of these O-glycans by sialic acid, by overexpressing the ST3Gal1 sialyltranferase enzyme, renders the cells resistant to galectin-1. Whereas ST3Gal1 expression in LNCaP cells did not completely mask all O-glycans because we still detected some PNA binding to the cells (Fig. 5A ), ST3Gal1 expression reduced susceptibility of LNCaP by >60%. This suggests that critical O-glycans bound by galectin-1 to trigger cell death were preferentially modified by ST3Gal1. Importantly, our group previously found that O-glycans on T cells are critical for susceptibility to galectin-1 (29, 30) . In T cells, elongation of O-glycans by core 2 GnT modifies several cell-surface glycoproteins, including CD45 and CD43, required for conferring susceptibility of CD45 + T cells to galectin-1 (30) . We have also recently determined that malignant T cells from some patients with cutaneous T-cell lymphoma have aberrant cell-surface glycosylation and are thus resistant to galectin-1-induced cell death (8) . Specifically, we identified malignant T cells from one patient with a single point mutation in core 2 GnT that abrogated enzyme activity and conferred galectin-1 resistance (46) . We found that core 2 GnT is highly expressed in parental PSA + LNCaP cells that are susceptible to galectin-1-induced death and markedly reduced in PSA À LNCaP cells that produce abundant galectin-1 and are resistant to galectin-1-induced cell death. Thus, we have now found reduced core 2 GnT expression or activity correlating with resistance to galectin-1-induced cell death in prostate cancer cells and T lymphoma cells. Whereas the LNCaP cell-surface glycoproteins that can be modified by core 2 GnT are not known, it is clear that LNCaP cells do not express CD45 and CD43, the glycoproteins on T cells that bear core 2 O-glycans and are receptors for galectin-1. Thus, a common O-glycan modification on different polypeptides may regulate susceptibility of both prostate cancer cells and T cells to galectin-1.
Masking glycan ligands by the addition of sialic acid is a common glycosylation change described in many types of cancer. As mentioned above, PSA from prostate cancer patients contains more terminal a2,3-linked sialic acid compared with PSA from patients with benign prostatic hyperplasia (18). As we have previously shown with T cells (39), overexpression of ST3Gal1 was an effective method to block O-glycan elongation on LNCaP cells, as ST3Gal1 competes with several O-glycan-modifying enzymes, including core 2 GnT, in the Golgi (42) , and increased ST3Gal1 expression made the LNCaP cells resistant to galectin-1-induced death. Increased sialylation of tumor cell glycans may enhance tumor cell adhesion, invasion, and resistance to apoptosis. Conversely, our results imply that reducing sialylation and/or increasing O-glycan branching in tumor cells may be an effective mechanism to enhance tumor cell susceptibility to death induced by endogenous galectin-1.
Whereas several features of the T-cell death pathway triggered by galectin-1 have been described, we know very little about the mechanism of galectin-1-induced death of prostate cells. As prostate cells do not express the T-cell glycoprotein receptors CD45, CD43, and CD7 that are involved in galectin-1-induced T-cell death, different prostate cell glycoproteins that bear the appropriate glycan ligands and bind galectin-1 may transmit the death signal into prostate cancer cells. In this regard, prostate cellsurface glycoproteins that have functions similar to those of CD45, CD43, and CD7 (i.e., tyrosine phosphatase, association with ezrin/ radixin/moesin cytoskeletal linker proteins, and induction of tyrosine and lipid kinase activities, respectively) may be good candidates for the prostate-specific glycoprotein receptors that bind galectin-1 and trigger cell death. Intriguingly, neutral endopeptidase (also known as CD10) is a prostate cell glycoprotein that, like CD43 on T cells, bears O-glycans, associates with ERM linker proteins, and facilitates apoptosis, and CD10 expression decreases during prostate cancer progression (47, 48) ; our lab is currently investigating the role of CD10 in LNCaP cell susceptibility to galectin-1.
Resistance to galectin-1-induced apoptosis would confer an obvious selective advantage to prostate cancer cells; however, why would galectin-1-resistant prostate cancer cells make and externalize endogenous galectin-1? As we have shown, PSA À LNCaP cells that are resistant to galectin-1-induced death synthesize high levels of galectin-1, compared with the galectin-1-sensitive PSA + LNCaP cells (32) . As mentioned above, galectin-1 in prostate cancer stroma has been proposed to provide an ''immunologic shield'' around tumor cells, preventing infiltration of tumor-specific CTLs (14, 35) . Indeed, loss of galectin-1 expression by melanoma cells increased CD8 T-cell attack of tumor cells in a murine model (34) . In this report, we have directly shown that prostate cancer cells expressing galectin-1, including PSA À LNCaP cells and PC-3 cells, induce rapid death of bound T cells, as detected by TUNEL analysis of the T cells, whereas PSA + LNCaP cells did not kill bound T cells. These data indicate that prostate cancer cells resistant to galectin-1-induced death could exploit endogenous galectin-1 to kill infiltrating T cells. Tumor evasion of an immune response contributes substantially to expansion of the primary tumor, outgrowth of residual disease following surgical resection, and survival of metastases; adjunct immunotherapy approaches have included increasing T-cell infiltration into the prostate by triggering tumor cell apoptosis, enhancing tumor antigen presentation, and potentiating T-cell responses by blocking inhibitory CTLA-4 signals (49, 50). As mentioned above, altering tumor cell glycosylation could restore susceptibility to galectin-1 produced by tumor cells as well as tumor-associated stroma and endothelium, to make tumor cells, rather than T cells, targets of galectin-1. In combination with strategies to augment T-cell responses, this approach may enhance the effectiveness of prostate cancer therapy.
